Evaluating antitumor activity of antiglypican-3 therapy in experimentally induced skin cancer in mice
- 7 July 2020
- journal article
- research article
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 313 (4) , 263-273
Abstract
Glypican-3 (GPC3) is considered as a cell surface heparan sulfate proteoglycan. It is overexpressed in skin cancer and promotes tumor progression and pathoKeywords
This publication has 35 references indexed in Scilit:
- Differential expression of glypican-3 (GPC3) in lung squamous cell carcinoma and lung adenocarcinoma and its clinical significanceGenetics and Molecular Research, 2015
- Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinomaEuropean Journal of Pharmacology, 2015
- Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendationsAdvances in Therapy, 2014
- Sunlight UV-Induced Skin Cancer Relies upon Activation of the p38α Signaling PathwayCancer Research, 2013
- Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006Archives of Dermatology, 2010
- The IGF-1/IGF-1R signaling axis in the skin: a new role for the dermis in aging-associated skin cancerOncogene, 2009
- Sarcophine-diol, a Chemopreventive Agent of Skin Cancer, Inhibits Cell Growth and Induces Apoptosis through Extrinsic Pathway in Human Epidermoid Carcinoma A431 CellsTranslational Oncology, 2009
- Identification of Soluble NH2-Terminal Fragment of Glypican-3 as a Serological Marker for Early-Stage Hepatocellular CarcinomaCancer Research, 2004
- Involvement of NF-κB signalling in skin physiology and diseaseCellular Signalling, 2003
- The Role of IGF-I in Human Skin and its Appendages: Morphogen as Well as Mitogen?Journal of Investigative Dermatology, 1997